Influence of dynamic flow environment on nanoparticle-protein corona: From protein patterns to uptake in cancer cells

Colloids and Surfaces B: Biointerfaces

Volumn 153, Issue , 2017, Pages 263-271

  Palchetti, Sara ^a,b   Pozzi, Daniela ^a,b   Capriotti, Anna Laura ^c   Barbera, Giorgia La ^c   Chiozzi, Riccardo Zenezini ^c   Digiacomo, Luca ^d   Peruzzi, Giovanna ^e   Caracciolo, Giulio ^a   Laganà, Aldo ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF CAMERINO   (Italy)

^e ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Cancer cells; Dynamic flow environment; Nanoparticles; Physiological environments; Protein corona

Indexed keywords

CELL CULTURE; CELLS; DISEASES; MOLECULAR BIOLOGY; NANOPARTICLES; PHYSIOLOGY; SHEAR FLOW; SHEAR STRESS; SURFACE CHEMISTRY;

CANCER CELLS; DYNAMIC FLOWS; FETAL BOVINE SERUM; NANOPARTICLE (NPS); PHYSIOLOGICAL ENVIRONMENT; PROTEIN CORONAS; PROTEIN INTERACTION; TARGETED DELIVERY;

PROTEINS;

NANOPARTICLE; PROTEIN CORONA;

ARTICLE; CANCER CELL; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DYNAMIC FLOW ENVIRONMENT; FETAL BOVINE SERUM; FLOW KINETICS; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF-7 CELL LINE; PEGYLATION; PROTEIN INTERACTION; PROTEIN TRANSPORT; SERUM; SHEAR STRESS; SURFACE CHEMISTRY; SURFACE PROPERTY; ANIMAL; BOVINE; CHEMISTRY; FLOW CYTOMETRY; METABOLISM;

ANIMALS; CATTLE; FLOW CYTOMETRY; HELA CELLS; HUMANS; MCF-7 CELLS; NANOPARTICLES; PROTEIN CORONA; SURFACE PROPERTIES;

EID: 85014354605     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2017.02.037     Document Type: Article

References (59)

1. [1] Chinen, A.B., Guan, C.M., Ferrer, J.R., Barnaby, S.N., Merkel, T.J., Mirkin, C.A., Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. Chem. Rev. 115 (2015), 10530–10574.
2. [2] Cole, J.T., Holland, N.B., Multifunctional nanoparticles for use in theranostic applications. Drug Deliv. Transl. Res. 5 (2015), 295–309.
3. [3] Smith, J.D., Morton, L.D., Ulery, B.D., Nanoparticles as synthetic vaccines. Curr. Opin. Biotechnol. 34 (2015), 217–224.
4. [4] Mahmoudi, M., Lynch, I., Ejtehadi, M.R., Monopoli, M.P., Bombelli, F.B., Laurent, S., Protein- nanoparticle interactions: opportunities and challenges. Chem. Rev. 111 (2011), 5610–5637.
5. [5] Monopoli, M.P., Åberg, C., Salvati, A., Dawson, K.A., Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7 (2012), 779–786.
6. [6] Walkey, C.D., Chan, W.C.W., Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41 (2012), 2780–2799.
7. [7] Del Pino, P., Pelaz, B., Zhang, Q., Maffre, P., Nienhaus, G.U., Parak, W.J., Protein corona formation around nanoparticles–from the past to the future. Mater. Horiz. 1 (2014), 301–313.
8. [8] Docter, D., Westmeier, D., Markiewicz, M., Stolte, S., Knauer, S., Stauber, R., The nanoparticle biomolecule corona: lessons learned–challenge accepted?. Chem. Soc. Rev. 44 (2015), 6094–6121.
9. [9] Hajipour, M.J., Laurent, S., Aghaie, A., Rezaee, F., Mahmoudi, M., Personalized protein coronas: a key factor at the nanobiointerface. Biomater. Sci. 2 (2014), 1210–1221.
10. [10] Hamad-Schifferli, K., Exploiting the novel properties of protein coronas: emerging applications in nanomedicine. Nanomedicine 10 (2015), 1663–1674.
11. [11] Hajipour, M.J., Raheb, J., Akhavan, O., Arjmand, S., Mashinchian, O., Rahman, M., et al. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale 7 (2015), 8978–8994.
12. [12] Salvati, A., Pitek, A.S., Monopoli, M.P., Prapainop, K., Bombelli, F.B., Hristov, D.R., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8 (2013), 137–143.
13. [13] Mirshafiee, V., Mahmoudi, M., Lou, K., Cheng, J., Kraft, M.L., Protein corona significantly reduces active targeting yield. Chem. Commun. 49 (2013), 2557–2559.
14. [14] Gaspar, R., Nanoparticles: pushed off target with proteins. Nat. Nanotechnol. 8 (2013), 79–80.
15. [15] Ciasca, G., Papi, M., Chiarpotto, M., Rodio, M., Campi, G., Rossi, C., et al. Transient state kinetic investigation of ferritin iron release. Appl. Phys. Lett., 100, 2012, 073703.
16. [16] Chiarpotto, M., Ciasca, G., Vassalli, M., Rossi, C., Campi, G., Ricci, A., et al. Mechanism of aluminium bio-mineralization in the apoferritin cavity. Appl. Phys. Lett., 103, 2013, 083701.
17. [17] Westmeier, D., Chen, C., Stauber, R.H., Docter, D., The bio-corona and its impact on nanomaterial toxicity. Eur. J. Nanomed. 7 (2015), 153–168.
18. [18] Deng, Z.J., Liang, M., Monteiro, M., Toth, I., Minchin, R.F., Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 6 (2011), 39–44.
19. [19] Walkey, C.D., Olsen, J.B., Guo, H., Emili, A., Chan, W.C., Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134 (2012), 2139–2147.
20. [20] Mortimer, G.M., Butcher, N.J., Musumeci, A.W., Deng, Z.J., Martin, D.J., Minchin, R.F., Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano 8 (2014), 3357–3366.
21. [21] Saha, K., Rahimi, M., Yazdani, M., Kim, S.T., Moyano, D.F., Hou, S., et al. Regulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein corona. ACS Nano 10 (2016), 4421–4430.
22. [22] Corbo, C., Molinaro, R., Parodi, A., Toledano Furman, N.E., Salvatore, F., Tasciotti, E., The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine 11 (2016), 81–100.
23. [23] Kumar, A., Bicer, E.M., Morgan, A.B., Pfeffer, P.E., Monopoli, M., Dawson, K.A., et al. Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid. Nanomed.: Nanotechnol. Biol. Med. 12 (2016), 1033–1043.
24. [24] Mahon, E., Salvati, A., Baldelli Bombelli, F., Lynch, I., Dawson, K.A., Designing the nanoparticle–biomolecule interface for targeting and therapeutic delivery. J. Controlled Release 161 (2012), 164–174.
25. [25] Prapainop, K., Witter, D.P., Wentworth, P. Jr, A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. J. Am. Chem. Soc. 134 (2012), 4100–4103.
26. [26] Caracciolo, G., Cardarelli, F., Pozzi, D., Salomone, F., Maccari, G., Bardi, G., et al. Selective targeting capability acquired with a protein corona adsorbed on the surface of 1, 2-dioleoyl-3-trimethylammonium propane/DNA nanoparticles. ACS Appl. Mater. Interfaces 5 (2013), 13171–13179.
27. [27] Mahmoudi, M., Sheibani, S., Milani, A.S., Rezaee, F., Gauberti, M., Dinarvand, R., et al. Crucial role of the protein corona for the specific targeting of nanoparticles. Nanomedicine 10 (2015), 215–226.
28. [28] Ritz, S., Schöttler, S., Kotman, N., Baier, G., Musyanovych, A., Kuharev, J. Jr, et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 16 (2015), 1311–1321.
29. [29] Corbo, C., Molinaro, R., Taraballi, F., Toledano Furman, N.E., Sherman, M.B., Parodi, A., et al. Effects of the protein corona on liposome–liposome and liposome–cell interactions. Int. J. Nanomed. 11 (2016), 3049–3063.
30. [30] Walkey, C.D., Olsen, J.B., Song, F., Liu, R., Guo, H., Olsen, D.W.H., et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8 (2014), 2439–2455.
31. [31] Liu, R., Jiang, W., Walkey, C.D., Chan, W.C., Cohen, Y., Prediction of nanoparticles-cell association based on corona proteins and physicochemical properties. Nanoscale 7 (2015), 9664–9675.
32. [32] Palchetti, S., Digiacomo, L., Pozzi, D., Peruzzi, G., Micarelli, E., Mahmoudi, M., et al. Nanoparticles-cell association predicted by protein corona fingerprints. Nanoscale 8 (2016), 12755–12763.
33. [33] Mahmoudi, M., Protein corona: the golden gate to clinical applications of nanoparticles. Int. J. Biochem. Cell Biol. 75 (2016), 141–142.
34. [34] Bigdeli, A., Palchetti, S., Pozzi, D., Hormozi-Nezhad, M.R., Baldelli Bombelli, F., Caracciolo, G., et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10 (2016), 3723–3737.
35. [35] Hadjidemetriou, M., Al-Ahmady, Z., Kostarelos, K., Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale 8 (2016), 6948–6957.
36. [36] Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R.F., Dawson, K., Kostarelos, K., In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles. ACS Nano 9 (2015), 8142–8156.
37. [37] Pozzi, D., Caracciolo, G., Digiacomo, L., Colapicchioni, V., Palchetti, S., Capriotti, A.L., et al. The biomolecular corona of nanoparticles in circulating biological media. Nanoscale 7 (2015), 13958–13966.
38. [38] Palchetti, S., Colapicchioni, V., Digiacomo, L., Caracciolo, G., Pozzi, D., Capriotti, A.L., et al. The protein corona of circulating PEGylated liposomes. Biochim. Biophys. Acta (BBA)-Biomembr. 1858 (2016), 189–196.
39. [39] Caracciolo, G., Pozzi, D., Capriotti, A.L., Marianecci, C., Carafa, M., Marchini, C., et al. Factors determining the superior performance of lipid/DNA/protammine nanoparticles over lipoplexes. J. Med. Chem. 54 (2011), 4160–4171.
40. [40] Caracciolo, G., Farokhzad, O.C., Mahmoudi, M., Biological identity of nanoparticles in vivo: clinical implications of the protein corona. Trends Biotechnol. 35 (2016), 257–264.
41. [41] Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M., Kraft, M.L., Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 75 (2016), 295–304.
42. [42] Caracciolo, G., Pozzi, D., Capriotti, A.L., Cavaliere, C., Foglia, P., Amenitsch, H., et al. Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. Langmuir 27 (2011), 15048–15053.
43. [43] Capriotti, A.L., Caracciolo, G., Caruso, G., Cavaliere, C., Pozzi, D., Samperi, R., et al. Analysis of plasma protein adsorption onto DC-Chol-DOPE cationic liposomes by HPLC-CHIP coupled to a Q-TOF mass spectrometer. Anal. Bioanal. Chem. 398 (2010), 2895–2903.
44. [44] Capriotti, A.L., Caracciolo, G., Caruso, G., Cavaliere, C., Pozzi, D., Samperi, R., et al. Label-free quantitative analysis for studying the interactions between nanoparticles and plasma proteins. Anal. Bioanal. Chem. 405 (2013), 635–645.
45. [45] Monopoli, M.P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., et al. Physical- chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133 (2011), 2525–2534.
46. [46] Barrán-Berdón, A.L., Pozzi, D., Caracciolo, G., Capriotti, A.L., Caruso, G., Cavaliere, C., et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29 (2013), 6485–6494.
47. [47] Perry, J.L., Reuter, K.G., Kai, M.P., Herlihy, K.P., Jones, S.W., Luft, J.C., et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 12 (2012), 5304–5310.
48. [48] Pozzi, D., Colapicchioni, V., Caracciolo, G., Piovesana, S., Capriotti, A.L., Palchetti, S., et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 6 (2014), 2782–2792.
49. [49] Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8 (2013), 772–781.
50. [50] Treuel, L., Docter, D., Maskos, M., Stauber, R.H., Protein corona–from molecular adsorption to physiological complexity. Beilstein J. Nanotechnol. 6 (2015), 857–873.
51. [51] Braun, N.J., DeBrosse, M.C., Hussain, S.M., Comfort, K.K., Modification of the protein corona–nanoparticle complex by physiological factors. Mater. Sci. Eng.: C 64 (2016), 34–42.
52. [52] Mahmoudi, M., Abdelmonem, A.M., Behzadi, S., Clement, J.H., Dutz, S., Ejtehadi, M.R., et al. Temperature: the ignored factor at the NanoBio interface. ACS Nano 7 (2013), 6555–6562.
53. [53] Lundqvist, M., Nanoparticles: tracking protein corona over time. Nat. Nanotechnol. 8 (2013), 701–702.
54. [54] Mortensen, N.P., Hurst, G.B., Wang, W., Foster, C.M., Nallathamby, P.D., Retterer, S.T., Dynamic development of the protein corona on silica nanoparticles: composition and role in toxicity. Nanoscale 5 (2013), 6372–6380.
55. [55] Lesniak, A., Salvati, A., Santos-Martinez, M.J., Radomski, M.W., Dawson, K.A., Åberg, C., Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 135 (2013), 1438–1444.
56. [56] Kelly, P.M., Åberg, C., Polo, E., O'Connell, A., Cookman, J., Fallon, J., et al. Mapping protein binding sites on the biomolecular corona of nanoparticles. Nat. Nanotechnol. 10 (2015), 472–479.
57. [57] Sieben, C., Kappel, C., Zhu, R., Wozniak, A., Rankl, C., Hinterdorfer, P., et al. Influenza virus binds its host cell using multiple dynamic interactions. Proc. Natl. Acad. Sci. 109 (2012), 13626–13631.
58. [58] Bouvier, B., Optimizing the multivalent binding of bacterial lectin LecA by glycopeptide dendrimers for therapeutic purposes. J. Chem. Inf. Model. 56 (2016), 1193–1204.
59. [59] Caracciolo, G., Liposome–protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomed. Nanotechnol. Biol. Med. 11 (2015), 543–557.